61
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

Ocriplasmin opens up new avenues in the therapy of vitreomacular traction

&
Pages 407-411 | Published online: 09 Jan 2014
 

Abstract

Until now, the only treatment available for severe symptomatic vitreomacular traction, has been pars-plana-vitrectomy. Now, there is evidence for a new minimally invasive surgical therapy: the results of two Phase III studies show that an intravitreal injection of ocriplasmin allows an enzymatic vitreolysis.

Financial & competing interests disclosure

AJ Augustin is consultant to Alcon and received speaker's honorary from Alcon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues

  • • Ocriplasmin is the only approved drug to treat vitreomacular traction and small macular holes.

  • • It is administered intravitreally.

  • • Ocular and systemic safety has been documented.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 608.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.